Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5528 | LDN-214117 |
| Potent and selective inhibitor of type I bone morphogenic protein (BMP) receptor ALK2 (IC50 = 24 nM). Shows preference for ALK1 and ALK2 over ALK3 and 164-fold selectivity for BMP6 inhibition (IC50 = 100 nM) over TGF-β1. Exhibits improved kinome selectivity over K 02288 (Cat.No. 4986) and low cytotoxicity. | |
| BCC5536 | Azimilide Dihydrochloride |
| Kv11.1 (hERG) channel blocker, blocks rapidly activating and slowly activating components of delayed rectifier K+ currents (IC50 of 0.4 mM and 3 mM, respectively). Also inhibits Na+/Ca2+ exchanger in vitro. Shows inhibition of Na+ currents, L-type Ca2+ currents and other K+ currents at high concentrations. | |
| BCC5560 | Hydroxychloroquine Sulfate |
| Autophagy inhibitor. Inhibits growth and induces apoptosis of renal cancer cells in vitro. Also inhibits TLR9. | |
| BCC5565 | Blasticidin S HCl |
| Antibiotic. Selection reagent for bis, bsr and BSD transformed cells. | |
| BCC5568 | PF-06463922 |
| High affinity and selective ALK and ROS1 inhibitor (Ki values are <0.02, <0.07 and 0.7 nM for ROS1, wild-type ALK and ALK-L1196M, respectively). Exhibits >100-fold selectivity for ROS1 over a panel of 204 other kinases. Inhibits proliferation of BaF3 cells containing crizotinib-resistant ROS1 mutation in vitro. Inhibits tumor growth in relevant mouse models. Orally available and brain penetrant. | |
| BCC5581 | CCG-1423 |
| Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid,LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs. | |
| BCC5597 | GSK 5959 |
| Potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. Inhibits BRPF1 interaction with histone H3.3. Cell permeable. | |
| BCC5598 | OXF BD 02 |
| Selective inhibitor of the first bromodomain of BRD4 (BRD4(1)) (IC50 = 382 nM). Exhibits 2-3-fold selectivity for BRD4(1) over the CBP bromodomain and has little affinity for a range of other bromodomains. Reduces viability of lung adenocarcinoma cell lines and attenuates proliferation of MV-4-11 leukemia cells. Cell permeable. | |
